Login

Brian Cox, SurgePays CEO, discusses current $SURG fundamentals and more in this interview.|Kevin Brian Cox. Chairman/CEO, SurgePays Inc ; 00:10:00

Share On Facebook Share On Twitter

Kevin Brian Cox. Chairman/CEO, SurgePays Inc ;

Recent Videos

00:17:08
Urasar is 100% Hayasa Metals Inc. owned; our exploration license over the Urasar mineral district
00:10:00
Dryden Gold Secures $20M+ War Chest, Delivers High-Grade Discoveries and Expands Drill Targets Across Gold Rock District|Trey Wasser,CEO & Director,Dryden Gold 1
00:10:00
Mitchell Services Targets $50–60M EBITDA as Rig Utilization Drives Earnings Upside| Andrew Elf,CEO,Mitchell Services Limited
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio

Suggestions

00:10:00
Exploring Francis Fukuyama's Political Ideas|Mathilde Fasting,Professor,University of Oslo
00:10:00
wealth grow Investment opportunities|MARK HENTEMANN,CEO,Quantum Capital
00:00:00
Chenghua Gu, PhD Professor of Neurobiology, HMS | Neural and Vascular Systems' Influence on the Brain
00:10:00
A Pillar of Australia's Financial Sector and Community Leadership|Chairman ,BWP Trust
00:10:00
Brian Wesson on Restarting Otso Gold Mine in Finland
00:10:00
We aim to be one of Indias most trusted pharmaceutical company|Glenn Smith,Managing Director,Novita Healthcare
00:10:00
Impact of Inflation on Value Investing: Insights from Francisco García Paramés - Cobas AM
00:10:00
Ludlow Manufacturing: Powering Steel Innovation | Alex Waser - CEO of bystronic ag
00:10:00
Macquarie Group's Fiscal Year 2024 Performance and Strategic Overview | Shemara Wikramanayake , CEO , Macquarie Asset Management .
00:10:00
The Diary of a CEO, with 10 million views, features New Marquardt Lechwerke AG.
00:10:00
Assessing Meta's Strategic Shift and Financial Outlook |Roger McNamee, Co-Founder, Elevation Partners.
00:10:00
Navigating Availability Bias in Investing: Insights from Allodium Investment Consultants | David J. Bromelkamp - CEO of Allodium Investment Consultants

© 2026 Nehu